Literature DB >> 32551816

Perinatal Hypoxia-Inducible Factor Stabilization Preserves Lung Alveolar and Vascular Growth in Experimental Bronchopulmonary Dysplasia.

Kellen Hirsch1,2, Elizabeth Taglauer3, Gregory Seedorf1,4,5, Carly Callahan6, Erica Mandell1, Carl W White4,5, Stella Kourembanas3, Steven H Abman1,4,5.   

Abstract

Rationale: Antenatal inflammation with placental dysfunction is strongly associated with high bronchopulmonary dysplasia (BPD) risk in preterm infants. Whether antenatal or postnatal HIF (hypoxia-inducible factor) augmentation can preserve lung structure and function and prevent pulmonary hypertension after intrauterine inflammation is controversial.
Objectives: To determine whether antenatal or postnatal prolyl-hydroxylase inhibitor (PHi) therapy increases lung HIF expression, preserves lung growth and function, and prevents pulmonary hypertension in a rat model of chorioamnionitis-induced BPD caused by antenatal inflammation.
Methods: Endotoxin (ETX) was administered to pregnant rats by intraamniotic injection at Embryonic Day 20, and pups were delivered by cesarean section at Embryonic Day 22. Selective PHi drugs, dimethyloxalylglycine or GSK360A, were administered into the amniotic space at Embryonic Day 20 or after birth by intraperitoneal injection for 2 weeks. Placentas and lung tissue were collected at birth for morphometric and Western blot measurements of HIF-1a, HIF-2a, VEGF (vascular endothelial growth factor), and eNOS (endothelial nitric oxide synthase) protein contents. At Day 14, lung function was assessed, and tissues were harvested to determine alveolarization by radial alveolar counts, pulmonary vessel density, and right ventricle hypertrophy (RVH).Measurements and Main
Results: Antenatal PHi therapy preserves lung alveolar and vascular growth and lung function and prevents RVH after intrauterine ETX exposure. Antenatal administration of PHi markedly upregulates lung HIF-1a, HIF-2a, VEGF, and eNOS expression after ETX exposure.Conclusions: HIF augmentation improves lung structure and function, prevents RVH, and improves placental structure following antenatal ETX exposure. We speculate that antenatal or postnatal PHi therapy may provide novel strategies to prevent BPD due to antenatal inflammation.

Entities:  

Keywords:  bronchopulmonary dysplasia; endotoxin; hypoxia-inducible factors; prolyl-hydroxylase inhibitors; pulmonary hypertension

Mesh:

Substances:

Year:  2020        PMID: 32551816      PMCID: PMC7560790          DOI: 10.1164/rccm.202003-0601OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  88 in total

1.  The Evolution of Bronchopulmonary Dysplasia after 50 Years.

Authors:  Steven H Abman; Eduardo Bancalari; Alan Jobe
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

2.  Impaired fetoplacental angiogenesis in growth-restricted fetuses with abnormal umbilical artery doppler velocimetry is mediated by aryl hydrocarbon receptor nuclear translocator (ARNT).

Authors:  Emily J Su; Hong Xin; Ping Yin; Matthew Dyson; John Coon; Kathryn N Farrow; Karen K Mestan; Linda M Ernst
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

3.  Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study.

Authors:  Roberta L Keller; Rui Feng; Sara B DeMauro; Thomas Ferkol; William Hardie; Elizabeth E Rogers; Timothy P Stevens; Judith A Voynow; Scarlett L Bellamy; Pamela A Shaw; Paul E Moore
Journal:  J Pediatr       Date:  2017-05-17       Impact factor: 4.406

Review 4.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

5.  Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization.

Authors:  Bernard Thébaud; Faruqa Ladha; Evangelos D Michelakis; Monika Sawicka; Gavin Thurston; Farah Eaton; Kyoko Hashimoto; Gwyneth Harry; Alois Haromy; Greg Korbutt; Stephen L Archer
Journal:  Circulation       Date:  2005-10-18       Impact factor: 29.690

6.  Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.

Authors:  Timothy D Le Cras; Neil E Markham; Rubin M Tuder; Norbert F Voelkel; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-09       Impact factor: 5.464

Review 7.  Hypoxia and Placental Development.

Authors:  Michael J Soares; Khursheed Iqbal; Keisuke Kozai
Journal:  Birth Defects Res       Date:  2017-10-16       Impact factor: 2.344

8.  Early Pulmonary Vascular Disease in Preterm Infants Is Associated with Late Respiratory Outcomes in Childhood.

Authors:  Peter M Mourani; Erica W Mandell; Maxene Meier; Adel Younoszai; John T Brinton; Brandie D Wagner; Sanne Arjaans; Brenda B Poindexter; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

9.  Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia.

Authors:  Tiziana Cotechini; Maria Komisarenko; Arissa Sperou; Shannyn Macdonald-Goodfellow; Michael A Adams; Charles H Graham
Journal:  J Exp Med       Date:  2014-01-06       Impact factor: 14.307

10.  Deferoxamine Improves Alveolar and Pulmonary Vascular Development by Upregulating Hypoxia-inducible Factor-1α in a Rat Model of Bronchopulmonary Dysplasia.

Authors:  Chang Won Choi; Juyoung Lee; Hyun Ju Lee; Hyoung-Sook Park; Yang-Sook Chun; Beyong Il Kim
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

View more
  14 in total

1.  SM22α cell-specific HIF stabilization mitigates hyperoxia-induced neonatal lung injury.

Authors:  Reiji Ito; Elizabeth A Barnes; Xibing Che; Cristina M Alvira; David N Cornfield
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-06-28       Impact factor: 6.011

2.  Microvesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Alveolar Type II Cell Proliferation and Attenuate Lung Inflammation in a Rat Model of Bronchopulmonary Dysplasia.

Authors:  Ou Zhou; Jingyi You; Xiaochuan Xu; Jiang Liu; Huijun Qiu; Chang Hao; Wenjing Zou; Wenjie Wu; Zhou Fu; Daiyin Tian; Lin Zou
Journal:  Stem Cells Int       Date:  2022-06-27       Impact factor: 5.131

Review 3.  Pulmonary Hypertension: The Hidden Danger for Newborns.

Authors:  Steven H Abman
Journal:  Neonatology       Date:  2021-05-05       Impact factor: 4.035

4.  Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis.

Authors:  Alison N Abele; Elizabeth S Taglauer; Maricar Almeda; Noah Wilson; Abigail Abikoye; Gregory J Seedorf; S Alex Mitsialis; Stella Kourembanas; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-08       Impact factor: 5.464

5.  Update in Pediatrics 2020.

Authors:  Erick Forno; Steven H Abman; Jagdev Singh; Mary E Robbins; Hiran Selvadurai; Paul T Schumacker; Paul D Robinson
Journal:  Am J Respir Crit Care Med       Date:  2021-08-01       Impact factor: 30.528

6.  TET-dependent GDF7 hypomethylation impairs aqueous humor outflow and serves as a potential therapeutic target in glaucoma.

Authors:  Peixing Wan; Erping Long; Zhidong Li; Yingting Zhu; Wenru Su; Yehong Zhuo
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

Review 7.  Insulin-like growth factor-1: A potential target for bronchopulmonary dysplasia treatment (Review).

Authors:  Shujian Zhang; Xue Luan; Huiwen Li; Zhengyong Jin
Journal:  Exp Ther Med       Date:  2022-01-05       Impact factor: 2.447

8.  Preempting Bronchopulmonary Dysplasia: Time to Focus on the Placenta?

Authors:  Bernard Thébaud
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 6.914

9.  PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice.

Authors:  Xiaomeng Feng; Xia Gao; Shuo Wang; Mengxiu Huang; Zhencheng Sun; Hengbei Dong; Haitian Yu; Guang Wang
Journal:  Front Med (Lausanne)       Date:  2021-06-29

10.  Revisiting the Role for HIF Stabilizers in Bronchopulmonary Dysplasia.

Authors:  Olivier Boucherat; Eric D Austin; Sebastien Bonnet
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.